About 28 results found for searched term "IRAK" (0.085 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M6258 | CA-4948 | IRAK |
| IRAK4-IN-2; CA4948 | ||
| CA-4948 is a selective, potent and orally active inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4) that regulates IRAK4 function in the TLR and IL-1R signaling cascades. CA-4948 has good pharmacokinetic characteristics and antitumor activity in vitro and in vivo. | ||
| M9340 | IRAK-1-4 Inhibitor I | IRAK |
| IRAK-1-4 Inhibitor I is an inhibitor of interleukin-1 receptor-associated kinase 1/4 (IRAK 1/4) with IC50s of 0.3 μM and 0.2 μM, respectively. | ||
| M14092 | IRAK4-IN-4 | IRAK |
| IRAK4-IN-4 is an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor with an IC50 of 2.8 nM. | ||
| M14093 | IRAK inhibitor 3 | IRAK |
| IRAK inhibitor 3 is an interleukin-1 (IL-I) receptor-associated kinase (IRAK) modulator. | ||
| M14094 | IRAK inhibitor 4 | IRAK |
| IRAK inhibitor 4 is an interleukin-1 receptor associated kinase 4(IRAK4) inhibitor. | ||
| M20680 | IRAK inhibitor 6 | IRAK |
| IRAK inhibitor 6 is a selective Interleukin-1 receptor-associated kinase 4(IRAK4) inhibitor with IC50 of 0.16 μM. | ||
| M20807 | IRAK4-IN-1 | IRAK |
| Compound 23 | ||
| IRAK4-IN-1 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor with IC50 of 7 nM. | ||
| M21388 | IRAK4-IN-20 | IRAK |
| IRAK4-IN-20 (Compound BAY-1834845) is an orally active IRAK4 inhibitor with an IC50 of 3.55 nM. IRAK4-IN-20 may be used in studies of acute respiratory distress syndrome (ARDS). | ||
| M27696 | IRAK inhibitor 1 | IRAK |
| IRAK inhibitor 1 is a potent IRAK-4 inhibitor with IC50 of 216 nM, is poorly active against JNK-1 and JNK-2 with IC50 of 3.801 μM, and >10 μM, respectively. | ||
| M29530 | PROTAC IRAK4 degrader-1 | PROTAC |
| PROTAC IRAK4 degrader-1 is a Cereblon-based PROTAC interleukin-1 receptor-associated kinase 4 (IRAK4) degrader, makes <20%, >20-50%, and >50% IRAK4 degradation at 0.01, 0.1, and 1 μM in OCI-LY-10 cells, respectively. | ||
| M29635 | PROTAC IRAK4 degrader-7 | PROTAC |
| KT-474; KYM-001 | ||
| PROTAC IRAK4 degrader-7 (Compound I-417) is a potentially first-in-class, orally active PROTAC IRAK4 degrader with antitumor activity for studies related to hidradenitis suppurativa (HS) and atopic dermatitis (AD). | ||
| M29657 | IRAK4-IN-6 | IRAK |
| IRAK4-IN-6 is an orally efficacious and selective IRAK4 inhibitor with an IC50 of 4 nM, and targetes MyD88 L265P mutant diffuse large B cell lymphoma. | ||
| M41998 | IRAK4-IN-25 | IRAK |
| IRAK4-IN-25 is an orally acitve and potent IRAK4 inhibitor (IC50=7.3 nM), with low clearance (Cl=12 mL/min/kg). | ||
| M41999 | IRAK4-IN-24 | IRAK |
| IRAK4-IN-24 is a potent IRAK4 inhibitor, with high clearance (Cl) and poor oral bioavailability. | ||
| M42000 | IRAK4-IN-27 | IRAK |
| IRAK4-IN-27 is a potent, selective inhibitor of IRAK4, with IC50 of 8.7 nM. | ||
| M42001 | PROTAC IRAK4 degrader-8 | IRAK |
| PROTAC IRAK4 degrader-8 is a PROTAC targeting to IRAK4 (IC50=15.5 nM). | ||
| M42002 | IRAK4-IN-28 | IRAK |
| IRAK4-IN-28 is an orally active IRAK4 inhibitor (IC50=8.9 nM). | ||
| M42003 | Zomiradomide | IRAK |
| IRAK degrader-1; KT-413 | ||
| Zomiradomide (IRAK degrader-1; KT-413) is a potent IRAK degrader. Zomiradomide (IRAK degrader-1; KT-413) is a degradation agent that targets the IRAK4 protein and can be used in studies related to immune system diseases. | ||
| M42004 | IRAK4-IN-26 | IRAK |
| IRAK4-IN-26 is a IRAK4 inhibitor (IC50: 6.2 nM). | ||
| M43248 | IRAK-4 Peptide substrate | Others |
| IRAK-4 Peptide substrate (IRAK-1 (360-380)) is a biological active peptide. | ||
| M43445 | PROTAC IRAK3 degrade-1 formic | PROTAC |
| PROTAC IRAK3 degrade-1 formic is a potent and selective degrader of IRAK3 (IC50=5 nM). | ||
| M54681 | IRAK4-IN-21 | IRAK |
| IRAK4-IN-21 is an orally potent, selective, and potent IRAK4 inhibitor with IC50 values of 5 and 56 nM for IRAK4 and TAK1, respectively.IRAK4-IN-21 potently inhibits the production of IL-23 (IC50=0.17 µM) and may be useful in studies related to autoimmune diseases such as plaque psoriasis and psoriasis vulgaris. arthritis). | ||
| M54674 | IRAK inhibitor 2 | IRAK |
| IRAK inhibitor 2 is an interleukin-1 receptor-related kinase 4 (IRAK4) inhibitor. | ||
| M54683 | PROTAC IRAK4 degrader-3 | IRAK |
| PROTAC IRAK4 degrader-3 is a von Hippel-Lindau based IRAK4 degrader PROTAC. | ||
| M54679 | IRAK-4 protein kinase inhibitor 2 | IRAK |
| IRAK-4 protein kinase inhibitor 2 is a potent interleukin 1 (IL-1) receptor-associated kinase 4 (IRAK-4) inhibitor with an IC50 value of 4 μM.IRAK-4 protein kinase inhibitor 2 can be used in the study of inflammatory and immune-related diseases. | ||
| M54685 | IRAK4-IN-22 | IRAK |
| IRAK4-IN-22 is an orally potent and selective potent IRAK4 inhibitor with IC50 values of 3 and 17 nM for IRAK4 and TAK1, respectively.In addition, IRAK4-IN-21 potently inhibits the production of IL-23 (IC50=0.10 µM), which may be useful in studies related to autoimmune diseases such as plaque psoriasis and psoriasis vulgaris. arthritis). | ||
| M54682 | IRAK inhibitor 4 (trans) | IRAK |
| IRAK inhibitor 4 (trans) is the trans form of IRAK inhibitor 4 and a potent inhibitor of IRAK4. | ||
| M65643 | Irak3 Rat Pre-designed siRNA Set | siRNA |
| Rat Irak3 Pre-designed siRNA Set contains three designed siRNAs for Irak3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control. Gene ID: 314870 | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
